

DESCRIPTION

| | |
|---------------------------|--|
| Species Reactivity | Mouse |
| Specificity | Detects mouse VE-Cadherin in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) Cadherin-8, rhCadherin-17, rhN-Cadherin, recombinant mouse (rm) E-Cadherin, or rmP-Cadherin is observed. |
| Source | Monoclonal Rat IgG _{2B} Clone # 162709 |
| Purification | Protein A or G purified from hybridoma culture supernatant |
| Immunogen | Mouse myeloma cell line NS0-derived recombinant mouse VE-Cadherin Asp46-Gln592 (Gly67 del, Ile69Asp, Lys70Gln) Accession # 2208309A |
| Conjugate | Alexa Fluor 594 Excitation Wavelength: 590 nm Emission Wavelength: 617 nm |
| Formulation | Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions. |

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

| | Recommended Concentration | Sample |
|-----------------------|----------------------------------|-------------------------------------|
| Flow Cytometry | 0.25-1 µg/10 ⁶ cells | bEnd.3 mouse endothelioma cell line |

PREPARATION AND STORAGE

| | |
|--------------------------------|---|
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Protect from light. Do not freeze. ● 12 months from date of receipt, 2 to 8 °C as supplied. |

BACKGROUND

The cadherin (Ca⁺⁺-dependent adherence) superfamily is a large group of membrane-associated glycoproteins that engage in homotypic, calcium-dependent, cell-cell adhesion events. The superfamily can be divided into at least five major subfamilies based on molecule gene structure, and/or extracellular (EC) and intracellular domains (1-4). Subfamilies include classical/type I, atypical/type II, and desmosomal-related cadherins (1-3). VE-Cadherin (vascular endothelial cadherin; also cadherin-5 and CD144) is a 125 kDa atypical/type II subfamily cadherin. Its subfamily classification is based principally on its genomic structure, as its physical structure is notably divergent from other type II subfamily members (2, 3). Mouse VE-Cadherin is synthesized as a 784 amino acid (aa) type I transmembrane (TM) preproprotein that contains a 24 aa signal peptide, a 21 aa prosequence, a 554 aa extracellular region (ECR), a 21 aa TM segment, and a 164 aa cytoplasmic domain (5, 6). The ECR contains five Ca⁺⁺-binding cadherin domains that are approximately 105 aa in length. Cadherin domains are comprised of two β-sheets that are oriented like bread in a sandwich. Although complex, the N-terminal cadherin domain mediates *trans* interactions, while the internal domains contribute to *cis* multimerizations (7). Mouse VE-Cadherin ECR is 92%, 77%, and 73% aa identical to rat, human and porcine VE-Cadherin ECR, respectively. VE-Cadherin is involved in the maintenance of endothelial permeability. In this regard, VE-Cadherin does not initiate new blood vessel formation; it maintains it once formed. Thus, when VE-Cadherin is downregulated, cells part and permeability increases (8). Notably, VEGF is known to promote vascular leakage, and apparently does so by inducing a β-arrestin-dependent endocytosis of VE-Cadherin (9). Part of this effect may be mediated by VE-Cadherin itself which is reported to increase the membrane half-life of VEGF R2 (10). VE-Cadherin acts homotypically at sites of zonula adherens. On each expressing cell, it is proposed that VE-Cadherin first forms a trimer, which then dimerizes with a trimeric counterpart *in-trans*. Alternatively, two *cis*-dimers could act *in-trans* to generate homotypic binding (11). In addition to cell adhesion, VE-Cadherin also is reported to mediate TGF-β receptor assembly. When clustered, VE-Cadherin enhances TβRII/TβRI assembly into an active receptor complex on endothelial cells (12). VE-Cadherin is expressed on endothelial cells, trophoblast cells, endothelial progenitor cells and embryonic hematopoietic cells (5, 8, 13, 14).

References:

1. Patel, S.D. *et al.* (2007) *Curr. Opin. Struct. Biol.* **13**:690.
2. Vestweber, D. (2008) *Arterioscler. Thromb. Vasc. Biol.* **28**:223.
3. Vincent, P.A. *et al.* (2004) *Am. J. Physiol. Cell. Physiol.* **286**:C987.
4. Cavallaro, U. *et al.* (2006) *Exp. Cell Res.* **312**:659.
5. Breier, G. *et al.* (1996) *Blood* **87**:630.
6. Huber, P. *et al.* (1996) *Genomics* **32**:21.
7. Pokutta, S. and W.I. Weis (2007) *Annu. Rev. Cell Dev. Biol.* **23**:237.
8. Crosby, C.V. *et al.* (2005) *Blood* **105**:2771.
9. Gavard, J. and J.S. Gutkind (2006) *Nat. Cell Biol.* **8**:1223.
10. Calera, M.R. *et al.* (2004) *Exp. Cell Res.* **300**:248.
11. Hewat, E.A. *et al.* (2007) *J. Mol. Biol.* **365**:744.
12. Rudini, N. *et al.* (2008) *EMBO J.* **27**:993.
13. Kogata, N. *et al.* (2006) *Circ. Res.* **98**:897.
14. Ema, M. *et al.* (2006) *Blood* **108**:4018.

Mouse VE-Cadherin Alexa Fluor® 594-conjugated Antibody

Monoclonal Rat IgG_{2B} Clone # 162709

Catalog Number: FAB1002T
100 µg

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.